

GNIPST BULLETIN 2024

(Pharmacy)



VOLUME-1, ISSUE- 1



Table of Contents

1

Message form Director
and Principal

2

Latest News/ Research
News

3

Campus News

4

Games



MESSAGE FROM HONORABLE DIRECTOR

I extend my heartfelt greetings to you all. At Guru Nanak Institute of Pharmaceutical Science and Technology, we are committed to fostering an environment of academic excellence, innovation and holistic development.

Our institution is dedicated in pursuit of Pharmaceutical Sciences.

We believe in nurturing inquisitive minds, encouraging critical thinking and developing skills of our beloved students. As we continue to grow and evolve, we remain steadfast in our mission to provide quality education and promote research and innovation.

We wholeheartedly appreciate your valued presence and involvement with Guru Nanak Institute of Pharmaceutical Science and Technology.

Prof. (Dr.) Abhijit Sengupta



MESSAGE FROM HONORABLE PRINCIPAL

It is my great pleasure to extend a warm welcome to you to Guru Nanak Institute of Pharmaceutical Science and Technology (GNIPST).

GNIPST is among the leading educational institutes of West Bengal aiming to provide quality pharmacy education to students.

GNIPST was established in 2005 and approved by PCI and affiliated to Maulana Abul Kalam Azad University of Technology, West Bengal. The institute is also the first pharmacy institute in West Bengal to receive accreditation from NAAC and NBA and the only private Pharmacy Autonomous institute in West Bengal. GNIPST is proud to be an NIRF Ranked Pharmacy Institute, being the 87th ranked institute in 2023.

We sincerely believe that rich values and traditions imbibed here along with proper educational facilities would carry the students to greater levels in their life.

Choose PHARMACY as a career and join with us to have a academically rewarding student life at GNIPST.

Prof. (Dr.) Lopamudra Datta



RECENT RESEARCHES



Comprehensive derivative synthesis method for development of new antimicrobial drugs:

READ MORE

<https://www.sciencedaily.com/releases/2024/07/240711215634.htm#:~:text=Efforts%20to%20combat%20the%20increasing,ichikawa%20of%20the%20Faculty%20of>

Efforts to combat the increasing threat of drug-resistant bacteria are being assisted by a new approach for streamlining the search for antimicrobial drug candidates, pioneered by researchers at Hokkaido University, led by Assistant Professor Kazuki Yamamoto and Professor Satoshi Ichikawa of the Faculty of Pharmaceutical Sciences. Their methods, developed together with researchers elsewhere in Japan and in the USA, are discussed in an article in the journal Nature Communications.

Now dengue tests can be done using origami paper

READ MORE

<https://www.ncbi.nlm.nih.gov/books/NBK143156/>

Three scientists and doctors from IIT Kharagpur and the School of Tropical Medicine have made an extraordinary "invention" using origami paper. Now, dengue tests can be done in just half an hour! Not only can they determine if someone has dengue, but they can also identify the serotype of the dengue virus, a time-consuming task, within 30 minutes.

Use of Clustered Apple Seeds in Colon Cancer Treatment

READ MORE

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973736/>

Clustered apple seeds, specifically from *Annona muricata* (commonly known as soursop, graviola, or clustered apple), have been studied for their potential therapeutic effects, including the treatment of colon cancer. The active compounds in these seeds, particularly Annonaceous acetogenins, have shown promise in scientific research due to their cytotoxic effects on cancer cells. The cytotoxic effects are primarily due to the disruption of mitochondrial function, leading to reduced energy production in cancer cells and the activation of apoptotic pathways. This mechanism helps in selectively targeting cancer cells while sparing normal cells to some extent. While preclinical studies show promise, the safety and toxicity of using clustered apple seeds and their extracts in humans need careful evaluation.

"The whole of science is nothing more than a refinement of everyday thinking."

— Albert Einstein



RECENT RESEARCHES



New research demonstrates potential for increasing effectiveness of popular diabetes, weight-loss drugs

READ MORE

<https://www.sciencedaily.com/releases/2024/07/240715170850.htm>

A network of proteins found in the central nervous system could be harnessed to increase the effectiveness and reduce the side effects of popular diabetes and weight-loss drugs, according to new research from the University of Michigan. The study, appearing today in the Journal of Clinical Investigation, focused on two proteins called melanocortin 3 and melanocortin 4 found primarily on the surface of neurons in the brain that play a central role in regulating feeding behavior and maintaining the body's energy balance.

Lecanemab Gains Approval in Israel for Early-Stage Alzheimer's Treatment

READ MORE

<https://www.prnewswire.com/news-releases/leqembi-approved-for-the-treatment-of-alzheimers-disease-in-israel-302195545.html>

Eisai Co., Ltd. And Biogen Inc. announced that lecanemab, a humanized anti-soluble aggregated amyloid-beta ($A\beta$) monoclonal antibody, has been approved in Israel for treating early stages of Alzheimer's disease (AD). LEQEMBI targets both soluble $A\beta$ aggregates (protofibrils) and insoluble $A\beta$ plaques, reducing their presence in the brain and slowing cognitive and functional decline. The approval is based on the successful Phase 3 Clarity AD study. LEQEMBI has also been approved in the U.S., Japan, China, South Korea, and Hong Kong. Eisai leads global development and commercialization, including in Israel.

Orchid Pharma Receives DCGI Approval for New Antibiotic Entity and Combination Therapy


READ MORE

<https://www.pharmaceutical-technology.com/news/dcgi-orchid-pharma-enmetazobactam/#:~:text=The%20company%20anticipates%20a%20successful,Cefepim%20to%20treat%20serious%20infections.>

Orchid Pharma, based in Chennai, has received approval from the Drugs Controller General of India (DCGI) to manufacture and market its new chemical entity, Enmetazobactam, as an Active Pharmaceutical Ingredient (API). Additionally, DCGI has approved the manufacturing and marketing of a combination of Cefepime and Enmetazobactam as a dry powder injectable for treating severe infections, including complicated urinary tract infections, hospital-acquired pneumonia, and bacteremia associated with these conditions. This approval aims to improve treatment options for serious infections in India and combat antimicrobial resistance. Orchid Pharma's Managing Director, Manish Dhanuka, expressed fulfillment in providing advanced and affordable treatment options to Indian patients and looks forward to the successful launch and distribution of these products.

NEW DRUG APPROVALS

JUNE 2024



Pyzchiva (ustekinumab-ttwe) Injection

- **Company:** Samsung Bioepis Co., Ltd.
- **Date of Approval:** June 28, 2024
- **Treatment for:** Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, Ulcerative Colitis.

Nypozi (filgrastim-txid) Injection

- **Company:** Tanvex BioPharma USA, Inc.
- **Date of Approval:** June 28, 2024
- **Treatment for:** Neutropenia, Neutropenia Associated with Chemotherapy,

Tepylute (thiotepa) Injection

- **Company:** Shorla Oncology
- **Date of Approval:** June 25, 2024
- **Treatment for:** Breast Cancer, Ovarian Cancer

Ahzantive (afibercept-mrbb) Injection

- **Company:** Formycon AG
- **Date of Approval:** June 28, 2024
- **Treatment for:** Macular Degeneration, Macular Edema Following Retinal Vein Occlusion, Diabetic Macular Edema, Diabetic Retinopathy

Ohtuvayre (ensifentrine) Inhalation Suspension

- **Company:** Verona Pharma plc
- **Date of Approval:** June 26, 2024
- **Treatment for:** COPD, Maintenance

PiaSky (crovalimab-akxz) Injection

- **Company:** Genentech, Inc.
- **Date of Approval:** June 20, 2024
- **Treatment for:** Paroxysmal Nocturnal Hemoglobinuria

LEARN

MORE




<https://www.drugs.com/newdrugs.html>

"The most effective way to do it, is to do it."

— Amelia Earhart

NEW DRUG APPROVALS

JUNE 2024



Sofdra (sofipronium) Topical Gel

- **Company:** Botanix Pharmaceuticals Ltd.
- **Date of Approval:** June 18, 2024
- **Treatment for:** Hyperhidrosis

1

Vigafyde (vigabatrin) Oral Solution

- **Company:** Pyros Pharmaceuticals, Inc.
- **Date of Approval:** June 17, 2024
- **Treatment for:** Infantile Spasms

2

Capvaxive (pneumococcal 21-valent conjugate vaccine) Injection - formerly V116

- **Company:** Merck
- **Date of Approval:** June 17, 2024
- **Treatment for:** Pneumococcal Disease Prophylaxis

3

Iqirvo (elafibranor) Tablets

- **Company:** Ipsen Biopharmaceuticals, Inc.
- **Date of Approval:** June 10, 2024
- **Treatment for:** Primary Biliary Cholangitis

4

Yimmugo (immune globulin intravenous, human-dira) Liquid for Intravenous Injection

- **Company:** Grifols USA, LLC
- **Date of Approval:** June 13, 2024
- **Treatment for:** Primary Immunodeficiency Syndrome

5

Rytelo (imetelstat) for Injection

- **Company:** Geron Corporation
- **Date of Approval:** June 6, 2024
- **Treatment for:** Myelodysplastic Syndrome

6

LEARN

MORE




<https://www.drugs.com/newdrugs.html>

"Research is what I'm doing when I don't know what I'm doing."

— Werner von Braun

Latest Generic Drug Approvals



PALBOCICLIB TABLETS 75 MG, 100 MG AND 125 MG

Approved: June 5, 2024 -
Synthon Pharmaceuticals, Inc.
Treatment for: Breast Cancer
Generic for: Ibrance Tablets

1

2

PHTERMINE HYDROCHLORIDE AND TOPIRAMATE EXTENDED RELEASE CAPSULES

- **Approved:** June 25, 2024 -
Actavis Laboratories FL, Inc.
- **Treatment for:** Obesity
- **Generic for:** Qsymia



3

AVANAFIL TABLETS 50 MG, 100 MG AND 200 MG

- **Approved:** June 14, 2024 - Hetero
Labs Limited
- **Treatment for:** Erectile
Dysfunction
- **Generic for:** Stendra



INDIUM IN-111 PENTETREOTIDE INJECTION KIT 3 MCI/ML

5

4

- **Approved:** July 1, 2024 - Sun Pharmaceutical
Industries, Inc.
- **Used for:** Diagnosis and Investigation
- **Generic for:** Octreoscan



BUPIVACAINE LIPOSOME INJECTABLE SUSPENSION 133 MG/10 ML

- **Approved:** July 1, 2024 - Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- **Used for:** Analgesia
- **Generic for:** Exparel

LEARN

MORE

<https://www.drugs.com/newdrugs.html>

DISEASE OUTBREAK NEWS



1. Avian Influenza A (H9N2) - India (11 June 2024) <https://www.who.int/emergencies/diseases-outbreak-news/item/2024-DON523>

Situation at a glance

On 22 May 2024, the International Health Regulations (IHR) National Focal Point (NFP) for India reported to WHO a case of human infection with avian influenza A(H9N2) virus detected in a child resident of West Bengal state in India. This is the second human infection of avian influenza A(H9N2) notified to WHO from India, with the first in 2019. The child has recovered and was discharged from hospital. According to the IHR (2005), a human infection caused by a novel influenza A virus subtype is an event that has the potential for high public health impact and must be notified to the WHO. Most human cases of infection with avian influenza A(H9N2) viruses are exposed to the virus through contact with infected poultry or contaminated environments. Human infection tends to result in mild clinical illness. Based on available information, further sporadic human cases could occur as this virus is one of the most prevalent avian influenza viruses circulating in poultry in different regions. With the currently available evidence, WHO assesses the current public health risk to the general population posed by this virus as low. However, the risk assessment will be reviewed should further epidemiological or virological information become available.

2. Mpox - Democratic Republic of the Congo (14 June 2024) <https://www.who.int/emergencies/diseases-outbreak-news/item/2024-DON522>

Situation at a glance

In December 2022, the Democratic Republic of the Congo declared a national outbreak of mpox and an incident management system has been in place since February 2023, based on the increasing number of reported cases. A new variant of clade I MPXV has been described in South Kivu. It carries predominantly APOBEC3-type mutations, indicating adaptation of the virus due to circulation among humans. This is the first documented sustained community transmission of the virus in the country. It is not known if this variant is more transmissible or leads to more severe disease than other clade I MPXV strains. Additionally, it carries gene deletions that affect diagnostics in the Democratic Republic of the Congo. To date, only clade I MPXV has been detected in the country, which in the WHO African region, reports the highest number of cases. In 2024, as of 26 May, a total of 7 851 mpox cases were reported in the Democratic Republic of the Congo, including 384 deaths (Case Fatality Rate (CFR) 4.9%). These cases were reported in 177 of the 519 (34%) health zones across 22 out of the 26 provinces (85%). The continuing development of the mpox outbreak in the Democratic Republic of the Congo remains concerning due to the continuing high incidence of mpox reported in endemic areas of the country in recent years with high case fatality, the geographic expansion to previously unaffected areas, the appearance of a novel strain of clade I MPXV, the observed sustained community transmission driven by sexual transmission and other forms of close physical contact in the eastern part of the country, resource constraints to respond over such a wide geographic area, limited public awareness of mpox, the insufficient availability of treatment kits and lack of vaccines to date, multiple competing public health priorities, and insecurity. Based on the situation, WHO assesses that the risk associated with mpox in the Democratic Republic of the Congo remains high.

Campus News



Our students, Sayan Saha, M.Pharm Pharmaceutical Biotechnology, 1st year and Hardeep Sign Jassal B.Pharm, 3rd Year have secured Science Academies' Summer Research Fellowship 2024 under leading Scientists of the Country.



Our students, Arnab Bakshi and Debtanu Bhattacharya, B.Pharm 4th Year have secured IPA Bengal Pharma & Healthcare Trust Scholarship 2024.



We are delighted to announce that Saikat Dutta, Sonu Prasad, and Srija Sana have been appointed as Scientific Content Developers at Trimplin. Their expertise promises to enhance our team's capabilities in delivering cutting-edge scientific content. Join us in welcoming them to our dynamic workforce as we look forward to their valuable contributions.



We are thrilled to announce that Mr. Dipanjan Mandal and Ms. Lopamudra Saha has been honored with prestigious International Research Str Award by ISSN 2024!



We are thrilled to announce that 15 students from Gnipst have been placed at Wipro as Associates. This achievement reflects their hard work and dedication, showcasing Gnipst's commitment to nurturing talent and fostering industry connections. Congratulations to all the students on this remarkable accomplishment. Here's to a bright future ahead!



Gnipst is delighted to host an International Faculty Development Program from June 25 to 29, 2024. This program aims to foster academic excellence through interactive sessions and workshops. Faculty members across disciplines are invited to participate and explore

innovative teaching practices and research methodologies. Don't miss this opportunity to engage with global experts and enhance your professional skills. Mark your calendars and join us for an enriching experience!



Gnipst has been honored with the "Best Pharmacy Institute in West Bengal" award (Uttoron) by TV9 Bangla, recognizing its excellence in pharmaceutical education, research, and innovation. This accolade highlights Gnipst's outstanding contributions to the field and its commitment to academic excellence.




Game Time

Crossword PH-1

Across 2.A cylindrical organelle composed mainly of a protein called tubulin(centriole) 4.The specialized DNA sequence of a chromosome that links a pair of sister chromatids (centromere) 5.A type of cell division that results in two exact daughter cells (mitosis) 6.A disease caused by an uncontrolled division of abnormal cells in apart of the body (cancer) 9.A deoxyribonucleic acid molecule with part or all of the genetic material of an organism (chromosome) 10.The stage in which the chromosomes move away from one another to opposite poles of the spindle (anaphase)

Down 1.The material of which the chromosomes of organisms are composed (chromatin) 3.The series of events that take place in a cell leading to duplication of its DNA (cell cycle) 7.A chromosome that has been newly copied or the copy of such a chromosome (chromatid) 8.The first stage of cell division (prophase)



QUIZ TIME



I am a water soluble vitamin. Due to my deficiency it can Cause beriberi in human body. Who am I? Q

I am present inside the cells with helix structure. I am responsible for synthesis of protein in human body. Guess who am I? A



I am neither acid nor base, by the addition of small quantities of either an acid or base I can change the pH. Who am I?

I am a piece of paper but I have significant value in health care system. Doctor has given the instructions regarding the medication on me. Who am I?

Stay tuned for to the next edition for a shout out to fastest correct answers!

Submit your answer



or



Editorial Board

Editor-in-Chief

Prof. (Dr.) Abhijit Sengupta

Managing Editors

Prof. (Dr.) Lopamura Datta

Associate Editors

Mr. Tushar Adhikari

Ms. Manjarima Ganguli

Editorial Board Member

Mrs. Indrani Banerjee Chakraborty

Mr. Arpan Dutta

Ms. Ananya Chandra

Ms. Parnasree Chakraborty

Ms. Lopamudra Saha

Mr. Sarthak Saha



COURSES OFFERED

PHARMACY UG COURSES

- Bachelor of Pharmacy (B.Pharm)

PHARMACY DIPLOMA COURSES

- Diploma in Pharmacy (D.Pharm)

PHARMACY PG COURSES

- M.Pharm in Pharmaceutics
- M.Pharm in Pharmacology
- M.Pharm in Pharmaceutical Chemistry
- M.Pharm in Quality assurance
- M.Pharm in Regulatory Affairs
- M.Pharm in Pharmacognosy
- M.Pharm in Pharmaceutical Biotechnology

Major
Recruiters



**Latest
news**



www.gnipst.ac.in



www.facebook.com



www.instagram.com



www.linkedin.com



www.youtube.com



api.whatsapp.com